GSK announced Tuesday it will acquire Nuvalent, a cancer drug developer, for $10.6 billion. CEO Luke Miels, six months into…
Read More

GSK announced Tuesday it will acquire Nuvalent, a cancer drug developer, for $10.6 billion. CEO Luke Miels, six months into…
Read More